Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis by Frédéric Mourcin et al.
MINI REVIEW ARTICLE
published: 05 September 2012
doi: 10.3389/fimmu.2012.00280
Stromal cell contribution to human follicular lymphoma
pathogenesis
Frédéric Mourcin1,2,3, Céline Pangault 1,2,4, Rada Amin-Ali 1,2, Patricia Amé-Thomas1,2,4 and KarinTarte1,2,3,4*
1 INSERM, UMR U917, Rennes, France
2 Université Rennes 1, Rennes, France
3 Etablissement Français du Sang, Bretagne, Rennes, France
4 Service ITeCH, Pôle de Biologie, CHU de Rennes, Rennes, France
Edited by:
Christopher G. Mueller, Centre
National de la Recherche Scientifique,
France
Reviewed by:
Mark C. Coles, University of York, UK
Laura Santambrogio, Albert Einstein
College of Medicine, USA
*Correspondence:
Karin Tarte, Faculté de Médecine,
INSERM, UMR U917, 2 Avenue du Pr
Léon Bernard, 35043 Rennes, France.
e-mail: karin.tarte@univ-rennes1.fr
Follicular lymphoma (FL) is the prototypical model of indolent B cell lymphoma displaying
a strong dependence on a specialized cell microenvironment mimicking normal germinal
center. Within malignant cell niches in invaded lymph nodes and bone marrow, external
stimuli provided by infiltrating stromal cells make a pivotal contribution to disease develop-
ment, progression, and drug resistance.The crosstalk between FL B cells and stromal cells
is bidirectional, causing activation of both partners. In agreement, FL stromal cells exhibit
specific phenotypic, transcriptomic, and functional properties. This review highlights the
critical pathways involved in the direct tumor-promoting activity of stromal cells but also
their role in the organization of FL cell niche through the recruitment of accessory immune
cells and their polarization to a B cell supportive phenotype. Finally, deciphering the inter-
play between stromal cells and FL cells provides potential new therapeutic targets with
the aim to mobilize malignant cells outside their protective microenvironment and increase
their sensitivity to conventional treatment.
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B CELL LYMPHOMAMICROENVIRONMENT
Human mature B cell lymphomas represent a heterogeneous
group of neoplasias characterized by recurrent genetic abnormal-
ities and pathway dependencies. Each lymphoma subtype could
be assigned to a peculiar stage of normal B cell differentiation,
as judged by gene expression profiling and phenotype (Shaffer
et al., 2012). In some of them, malignant B cell proliferation,
survival, and drug resistance are strongly dependent on a com-
bination of external stimuli delivered by the microenvironment
within specific niches in invaded lymph nodes (LN) and bone
marrow (BM; Burger et al., 2009). This is particularly true in fol-
licular lymphoma (FL), the most frequent indolent lymphoma,
which results from the malignant transformation of germinal cen-
ter (GC)-derived B cells (Figure 1). Whereas over 90% of FL cases
display a BCL2/IGH translocation, this early event, occurring as
a mistake of V(D)J recombination in the BM, could be detected
at low frequency within recirculating post-GC memory B cells of
most healthy individuals (Roulland et al., 2011). These t(14;18)pos
cells exhibit additional characteristics that stand as hallmarks of
FL cells; i.e., CD10 expression, unleashed AID activity, persistence
of surface IgM despite active class-switch recombination on the
translocated allele; are thus called follicular-lymphoma like cells.
Given that the actual prevalence of FL is around 0.03%, it is
clear that FL pathogenesis requires additional oncogenic events
as well as a progressive modification of the composition and
organization of tumor microenvironment (Bende et al., 2007).
Among the recurrent complementary hits identified in FL patients,
several alterations target the transcriptional and epigenetic path-
ways including inactivation of CREBBP/EP300 acetyltransferases,
MLL2 methyltransferase, and MEF2B, involved in the recruitment
of histone-modifying enzymes, and gain-of-function mutations
of EZH2 polycomb gene (Shaffer et al., 2012). Recently, a fre-
quent inactivation of the soluble inhibitory receptor EPHA7 was
also reported (Oricchio et al., 2011). This inactivation hinders the
blockade by EPHA7 of the ephrin migratory pathway induced by
cell–cell contact.
In agreement, genetic alterations and modification of the
microenvironment are not independent transformation mecha-
nisms since several FL-specific genetic alterations are not onco-
genic per se but favor specific interactions with neighboring cells.
Among them, the frequent mutations of TNFRSF14/HVEM could
play a role in the maintenance of the functional tumor cell
niche (Launay et al., 2012; Pasero et al., 2012). In fact, bind-
ing of HVEM to its receptor BTLA delivers an inhibitory sig-
nal and BTLA is strongly expressed on FL-supportive follicular
helper T cells (TFH) within malignant follicles (see below). In
addition, nearly all FL-derived immunoglobulin variable regions
display unusual sites for N-linked glycosylation, introduced dur-
ing somatic hypermutation process, and reflecting positive selec-
tion associated to lymphomagenesis (Stevenson and Stevenson,
2012). Glycans added to these motifs are atypical in terminat-
ing at high mannose that interact with C-type lectins on the
surface of surrounding cells and trigger BCR engagement. This
functional bridge could mimic for continuous antigen stimu-
lation to promote survival of FL cells (Coelho et al., 2010).
About 30% of FL finally transform into aggressive diffuse large
B cell lymphomas (DLBCL) that are less dependent on their
microenvironment.
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FIGURE 1 | Follicular lymphoma pathogenesis.The first step of follicular
lymphoma (FL) development occurs in the bone marrow as a mistake in
V(D)J rearrangement and leads to the ectopic expression of the
antiapoptotic protein bcl2. After antigen encounter, naive B cells harboring
the t(14;18) reach the germinal center where they display a selective growth
advantage and could extensively recirculate as atypical IgMpos low affinity
memory B cells called follicular-lymphoma like cells (FLLC). Iterative
reentries into germinal centers allow the acquisition of additional genetic
alterations. The relationship between FLLC and FL is not formerly
demonstrated but the hypothesis is that FLLC contain premalignant
intermediates that could transform in some patients into FL. FL cells remain
strongly dependent on bidirectional crosstalk with heterogeneous stromal
cells, including activated fibroblastic reticular cells (FRC), altered follicular
dendritic cells (FDC), and perhaps marginal reticular cells (MRC) of unknown
origin and infiltrating immune cells including tumor-associated macrophages
(TAM) and follicular helper T cells (TFH). FL also developed in the bone
marrow where B-cell clones could evolve independently within ectopic
specific FL-supportive niches.
Microarray analyses have revealed that the clinical outcome
of FL patients is primarily predicted by molecular features of
non-malignant cells (Dave et al., 2004). Moreover, immunohis-
tochemical studies have identified a large panel of predictive
markers reflecting the number, activation, and/or spatial distribu-
tion of infiltrating immune non-B cell subsets, including tumor-
associated macrophages (TAM) and CD4pos T cells (Relander et al.,
2010). Besides immune cells, three main stromal cell subsets have
been described within normal LN: (i) fibroblastic reticular cells
(FRC) recruit mature dendritic cells and naïve B and T lympho-
cytes through the production of CCL19, CCL21, and CXCL12,
promote cell–cell interactions within the T cell zone, and are
involved in T cell self-tolerance and tissue tropism imprinting;
(ii) follicular dendritic cells (FDC) drive CXCL13-dependent B cell
attraction within GC where they concentrate unprocessed antigens
and promote the selection of high affinity B cells; (iii) marginal
reticular cells (MRC) deliver small antigens to cognate B cells
through a network of follicular conduits (Mueller and Germain,
2009; Roozendaal and Mebius, 2011). It has long been assumed
that some tumor conducive stromal cell niches are shaped within
FL LN. In fact, FL LN exhibit a uniform and marked activation of
transglutaminase expressing FRC network (Thomazy et al., 2003),
whereas FDC display an undifferentiated phenotype (Chang et al.,
2003; Jin et al., 2011). MRC have never been evaluated in human
lymphomas. More generally a functional characterization of the
heterogeneous stromal cell network that is found within malignant
follicles is currently lacking. In addition, the in situ distribution of
lymphoid stromal cell subsets relative to malignant B cells and to
the other FL-supporting cell subsets and their activation status in
malignant follicles remains unknown.
Follicular lymphoma is generally a disseminated disease and
BM is involved in up to 70% of patients at diagnosis (Can-
ioni et al., 2004). BM infiltration is characterized by the ectopic
development of heterogeneous lymphoid-like stromal cells of
unknown origin that are found admixed with malignant B cells
and CD4pos T cells among nodular aggregates (Vega et al., 2002).
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Even if BM malignant B cells retain their main follicular features,
several morphologic, phenotypic, and genetic differences have
been reported among tumor cells found within LN and BM. In
particular, BM FL cells are characterized by a lower cytological
grade and proliferation (Bognar et al., 2005; Rajnai et al., 2012),
and exhibit a distinct transcriptomic profile revealing a downreg-
ulation of genes involved in cell proliferation and DNA repair (our
unpublished data). In addition, despite a common clonal origin,
analysis of intraclonal evolution reveals that a significant part of
the BM infiltration evolves independently from the tumor clones
detected in the LN indicating that BM provides a specific non-
lymphoid malignant cell niche (Bognar et al., 2005; Ruminy et al.,
2008). Recently, major differences in the cell composition of BM
and LN microenvironments have been highlighted (Rajnai et al.,
2012; Wahlin et al., 2012) thus paving the way for dedicated stud-
ies evaluating the impact of these variations on the behavior of
malignant FL cell clones.
Several experimental limitations have hampered a full under-
standing of the role of stromal cells in FL pathogenesis: (i) the
lack of B cell line reflecting the untransformed indolent stage of
FL leading to the use of aggressive GC-lymphoma cell lines; (ii)
the limited accessibility of tumor biopsies and the high propen-
sity of primary FL cells to undergo apoptosis in vitro; (iii) the
impossibility to maintain fully functional human FDC in cul-
ture; (iv) the heterogeneity of stromal cell subsets that remain
poorly understood in human; (v) the inherent flaws of human FL
B cell xenotransplantation into immunocompromised mice that
are devoid of structured secondary lymphoid organs; (vi) the lack
of validated relevant mouse model of FL. Nevertheless, even if
these pitfalls should be carefully kept in mind, some recent stud-
ies have provided interesting results about lymphoma-permissive
stromal cells, revealing both a direct B cell supportive effect and
an indirect activity on the orchestration of the FL cell niche.
DIRECT PROTUMORAL ACTIVITIES OF STROMAL CELLS
Interplay between lymphoma cells and their microenvironment
provides pivotal signals for malignant cell recruitment and growth
(Figure 2). First, stromal cells have been involved in the homing
of FL B cells that display a CXCR4hiCXCR5hiCCR7lo phenotype,
resembling to normal GC B cells (Lopez-Giral et al., 2004). We
have in particular identified the CXCR4-ligand CXCL12 as the
central chemokine in the recruitment of FL cells by both BM and
LN-derived stromal cells (Amé-Thomas et al., 2007). Interestingly,
CXCL13 has an additive effect with CXCL12 for the migration of
FL cells in vitro (Husson et al., 2002) and these two chemokines,
both produced by FDC in vivo, could contribute to the follicular
localization of malignant cells. In the Eµ-Myc transgenic mouse
model, CCR7 was elegantly reported to drive the specific homing
of malignant B cells to the T cell zone where their promote the
formation of a lymphoma-supportive stromal cell niche (Rehm
et al., 2011). The potential role of CCR7 in human FL is less clear,
given its low expression on malignant clones. However, we recently
underlined using Affymetrix microarrays that CCR7 expression is
low but upregulated in FL cells compared to normal centroblasts
and centrocytes (our unpublished data). The cues that guide nor-
mal GC B cell migration have been recently described in mice
and involve fine coregulation of CCR7, sphingosine 1-phosphate
FIGURE 2 | Follicular lymphoma cell niche. (A) Stromal cells recruit and
support directly the growth of FL B cells through a combination of adhesion
molecules, chemokines, and cytokines. Their supportive properties are
strongly influenced by the local cytokine context, in particular by TNF-α and
LT-α1β2 that are overexpressed by malignant B cells and promote lymphoid
stromal cell differentiation. (B) FL-MSC overexpress the chemokine CCL2
that promotes monocyte recruitment and polarization into TAM-like cells.
FL-TAM overexpress IL-15 that triggers, in cooperation with TFH-derived
CD40L, STAT5-dependent FL B cell activation. (C) FL-TFH overexpress
TNF-α and LT-α1β2, which favor stromal cell engagement into FRC
differentiation, but also IL-4 that drive STAT6-dependent B-cell activation and
contribute to the induction of TAM phenotype.
(S1P) receptor type 2 (SIPR2, also called S1P2), and Epstein-Barr
virus-induced gene 2 (EBI2, also known as GPR183) whose ligands
are produced by various lymphoid stromal cell subsets. CCR7 is
the receptor for CCL19/CCL21 produced by FRC of the T cell
zone. SIPR2 belongs to the family receptors for S1P, a lipid sig-
naling molecule presents in a decaying gradient in the follicle.
S1PR2 engagement by S1P inhibits cell migration and is involved
in the retention of GC B cells. Finally, the EBI2 ligand 7α,25-
dihydroxycholesterol is suggested to be present at high levels in
outer follicle and interfollicular regions. Briefly, normal antigen-
activated B cells upregulate CCR7 and EBI2 and localize to the
T-B border zone before migrating to the outer follicle region. By
day 4, the downregulation of CCR7 and EBI2, and the upregula-
tion of S1PR2 direct their movement and their confinement to the
follicle center, allowing GC formation (Pereira et al., 2010; Green
and Cyster, 2012). Interestingly, S1PR2 is downregulated in FL
whereas EBI2 is similarly expressed in FL cells and normal GC B
cells (our unpublished results). How the specific migratory profile
of FL B cells compared to their normal counterpart, i.e., similarly
high expression of CXCR4 and CXCR5, similarly low expression of
EBI2, higher expression of CCR7, and lower expression of S1PR2,
could be involved in their dissemination pattern is a fascinating
issue. In addition, even if the mechanisms of S1PR2 lymphoma
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suppressor function remain to be elucidated, S1PR2-deficient mice
develop tumors displaying histologic and molecular features of
GC-derived DLBCL and S1PR2 is aberrantly mutated in 26% of
human DLBCL (Cattoretti et al., 2009).
Besides migration, stromal cells provide essential survival fac-
tors to FL B cells. Among them, hedgehog (Hh) ligands are secreted
by BM and LN stromal cells, including FRC and FDC, and prevent
spontaneous normal and malignant GC B cell apoptosis (Sacedon
et al., 2005; Dierks et al., 2007). In addition, paracrine Hh signal-
ing induces the upregulation of the drug transporter ATP-binding
cassette (ABC) G2 and could be involved in stroma-mediated
chemotolerance in indolent lymphomas (Singh et al., 2010). The
gain of cell-autonomous activation of Hh pathway in DLBCL com-
pared to FL, likely contributes to stroma-independence in this
aggressive disease (Kim et al., 2009). Drug resistance has also been
associated to the induction by stromal cells of microRNA-181a in
malignant B cells, promoting a downregulation of the proapop-
totic protein Bim (Lwin et al., 2010). However, whereas regulation
of miRNA expression in lymphoma cells by stromal cells is prob-
ably a more common event than previously anticipated (Lin et al.,
2011), the mechanisms of this modulation remain unsolved. VLA-
4-dependent adhesion to stromal cells also protects FL B cells
from apoptosis induced by therapeutic antibodies, in particular
the anti-CD20 antibody rituximab (Mraz et al., 2011). Interest-
ingly, the VLA-4-ligand VCAM-1/CD106 is upregulated during
lymphoid stroma differentiation with a very strong expression in
FDC. BAFF, IL-15, and HGF are also produced by FDC and have
been proposed to contribute to the antiapoptotic effect of stromal
cells on normal and malignant GC B cell growth (Park et al., 2004;
Tjin et al., 2005, 2006; Mueller et al., 2007; Lwin et al., 2009; Epron
et al., 2012), whereas the role of FDC-derived Wnt5a and Notch
ligands in GC-derived lymphomas has not been explored to date
(Yoon et al., 2009; Kim et al., 2012).
Importantly, neoplastic B cell-stroma interaction should really
be considered as a bidirectional crosstalk. We have previously
demonstrated that human secondary lymphoid organs contain
bona fide mesenchymal stromal cells (MSC) that could be com-
mitted, like BM-MSC, to FRC differentiation in response to a
combination of tumor necrosis factor (TNF)-α and lymphotoxin
(LT)-α1β2, the two main factors involved in the differentiation and
maintenance of secondary lymphoid organs (Amé-Thomas et al.,
2007). These FRC-like cells are more powerful than resting MSC
to support malignant B cell survival. Moreover, malignant B cells
themselves could trigger such FRC engagement, at least in part
through the release of high levels of TNF-α and LT-α1β2 (Guillo-
ton et al., 2012). In agreement, MSC obtained from invaded BM
of FL patients (FL-MSC) are already committed to a FRC-like dif-
ferentiation, and support more efficiently the growth of malignant
B cells than MSC obtained from BM of healthy donors (HD-
MSC). FL-MSC display a specific gene expression profile (Guillo-
ton et al., 2012) and it would be of major importance to identify the
mechanisms of their increased direct tumor-promoting capacity.
Finally, the activity of stromal cells on malignant B cells could
be modulated depending on the cytokine context. We have demon-
strated that human MSC, in particular after commitment to
a FRC-like phenotype, could express indoleamine-2,3 dioxyge-
nase in response to interferon (IFN)-γ signaling, leading to an
inhibition of normal and malignant B cell proliferation but not
survival (Maby-El Hajjami et al., 2009). Of note, IFNG is upreg-
ulated within FL microenvironment, compared to reactive non-
malignant LN. Similarly, mice FRC could express nitric oxide
synthase 2 after priming by IFN-γ and could thereafter inhibit
T cell proliferation to control T cell expansion (Lukacs-Kornek
et al., 2011; Siegert et al., 2011). In addition, it has been suggested
that adhesion of lymphoma B cells to BM stroma could induce a
p27-dependent reversible cell cycle arrest, promoting cell survival,
and drug resistance (Lwin et al., 2007). Finally, stromal cells are
well known to secrete tumor-transforming growth factor (TGF)-
β that inhibits the proliferation of GC-derived B cell lines in a
Smad1-dependent manner (Munoz et al., 2004). Altogether these
data demonstrate that stromal cells finely regulate the behavior
of lymphoma B cells that, in turn, affect their differentiation and
activation.
INDIRECT PROTUMORAL ACTIVITIES OF STROMAL CELLS
Besides this direct lymphoma-supportive activity, stromal cells
could also interact with non-malignant tumor-infiltrating cells
and orchestrate FL cell niches. We have in particular demonstrated
that FL-MSC overexpress CCL2 at both RNA and protein lev-
els compared to HD-MSC (Guilloton et al., 2012). Interestingly
CCL2 is detectable at higher levels within FL-invaded BM com-
pared to normal BM. Moreover, CCL2 is upregulated in HD-MSC
by coculture with malignant B cells in a TNF-α-dependent man-
ner. Tumor-derived CCL2 recruits monocytes in several malignant
models (Roca et al., 2009; Qian et al., 2011). We have demonstrated
that CCL2 specifically contributes to monocyte recruitment by
FL-MSC that in turn trigger their differentiation toward a proan-
giogenic and anti-inflammatory TAM-like phenotype (Guilloton
et al., 2012). Furthermore, stromal cells and macrophages cooper-
ate to sustain malignant B cell survival and proliferation in vitro.
The reverse activity of macrophages on MSC remains to be eval-
uated in this context. The poor prognostic value of a high TAM
content in FL patients treated with conventional chemotherapy has
been reproducibly documented (Relander et al., 2010). However
the precise mechanism of the supportive activity of macrophages
toward neoplastic B cells remains unknown. Among the candi-
dates, we recently demonstrated that purified FL-TAM overexpress
IL-15 that cooperates with T cell-derived CD40L signal to sustain
FL cell growth (Epron et al., 2012). In DLBCL, BAFF was also pro-
posed as a monocyte-derived survival factor (Mueller et al., 2007).
Another highly interesting signaling pathway is the expression of
C-type lectins by myeloid cells that could crosslink the mannosy-
lated FL BCR independently of antigen specificity (Stevenson and
Stevenson, 2012).
Another crucial FL-supportive cell subset is the CD4pos
CXCR5hiICOShiPD-1hi TFH compartment. TFH provide survival
signals to antigen-selected normal GC B cells and help them to
achieve class-switch recombination and terminal differentiation
into antibody-secreting plasma cells (Crotty, 2011). In human,
TFH are also a major source of CXCL13 within follicles. We have
first demonstrated that TFH could be found in very high numbers
within the FL cell niche and efficiently support the survival of FL
cells in vitro, unlike non-TFH CD4pos T cells (Amé-Thomas et al.,
2012). In agreement, FL-TFH overexpress several genes directly
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involved in B cell activation, in particular CD40LG and IL4, and
we confirmed the importance of the TFH-dependent IL4 centered
pathway (Pangault et al., 2010). Interestingly, compared to tonsil-
TFH, FL-TFH also overexpress some genes involved in the crosstalk
with stromal cells, in particular TNF and LTA, that could favor the
differentiation and maintenance of lymphoid stromal cells and the
production of CCL2. Lymphoid stromal cells favor TFH survival
in vitro (our unpublished results) suggesting another positive loop
that sustains lymphomagenesis.
Follicular lymphoma cell niche should be thus considered as
a highly intricate network of heterogeneous cell subsets where
stromal cells directly promote tumor growth but play also a cen-
tral role as global organizers of the malignant microenvironment
through the regulation of non-B cell recruitment, survival, and
polarization.
STROMAL CELLS AS THERAPEUTIC TARGETS IN LYMPHOMA
Given the preeminent role of stromal cells within FL microen-
vironment, they progressively emerged as promising therapeutic
targets in this essentially incurable disease. A first approach is
to transiently mobilize malignant B cells outside their protective
niches to render them more sensitive to chemo- and immunother-
apy. CXCR4 antagonists, such as plerixafor (AMD3100), could
be combined with drugs targeting the malignant cells, such as
anti-CD20 antibodies, to increase their activity (Hu et al., 2012).
Cell-penetrating lipidated peptides targeting CXCR4 intracellular
domains also significantly increase the antitumoral activity of rit-
uximab in vitro and in vivo (O’Callaghan et al., 2012). Anti-VLA-4
antibody natalizumab has been evaluated as an alternative stromal
adhesion-disruptive drug (Mraz et al., 2011). Finally lenalidomide,
an immunomodulatory drug clinically active in several mature B
cell malignancies and under evaluation in FL, could disrupt B
cell-stroma interaction through a decrease in both CXCL12 pro-
duction by stromal cells (Wobus et al., 2012) and RhoH expression
in malignant B cells (Troeger et al., 2012). Interestingly, the Btk
inhibitor PCI-32765 has been initially developed to target BCR
signaling but it also impairs the chemokine-induced adhesion and
migration of primary chronic lymphocytic leukemia B cells (de
Rooij et al., 2012). Similar results have been obtained with Syk and
PI3K inhibitors and a recent study suggests that the Syk-mTOR
pathway is involved in FL cell invasion, through the regulation of
metalloproteinase-9 (MMP-9) and angiogenesis, as an upstream
regulator of vascular endothelial growth factor (VEGF; Fruchon
et al., 2012). Collectively, these results demonstrate that these
antagonists of BCR-related kinases could also affect lymphoma cell
homing and retention within specific niches. Surface molecules,
growth factors, or signaling pathways involved in the bidirectional
crosstalk between malignant B cells and stromal cells also repre-
sent individual attractive therapeutic targets even if the causative
lymphoma-driven signals remain to be precisely defined.
CONCLUDING REMARKS
In vitro and in vivo studies corroborate the hypothesis that lym-
phoid BM and LN stromal cells play a central role in the devel-
opment, growth, progression, and drug resistance in FL. The
mechanisms of the crosstalk between malignant B cells and stro-
mal cells are currently the subject of intensive research and several
major questions remain unsolved. Whether or not the concept
of cancer stem cells applies to this disease and, if true, what are
their specific cell niches remains to be explored and could have
major therapeutic consequences. Another important issue is the
specificity of FL cell niches. Are they shared with premalignant
follicular-lymphoma like cells or are they progressively induced
by the contact with malignant cells? A detailed comparison of
stromal cell niches in BM versus LN and their longitudinal study
at diagnosis in the context of minimal residual disease and in
relapse would be helpful to define the minimal but essential cell
components that support FL cells and rescue them from drug
cytotoxicity. It has also to be understood how such a support-
ive stromal microenvironment is assembled, in particular outside
LN. The exact origin of ectopic FRC and FDC, and their rela-
tionships with local MSC should be further analyzed. Finally,
developing new tools to better understand the functional het-
erogeneity of FL stroma may provide innovative strategies to
disarm the vicious circle where stromal cells support malignant
B cells that in turn convert their niche into a fully supportive
microenvironment.
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